GRAIL, Inc. is a commercial-stage healthcare company focused on early cancer detection at population scale. The company develops and sells Galleri, a multi-cancer early detection (MCED) test that screens for many types of cancer from a single blood draw by analyzing methylation patterns in cell-free DNA to identify a cancer signal and predict its tissue of origin. GRAIL serves healthcare providers, employers, digital health platforms, payors, and life insurance providers, with a significant presence in the United States and the United Kingdom. Key partnerships include collaborations with the U.S. Department of Veterans Affairs, the National Health Service (NHS) England, and AstraZeneca for companion diagnostic development. The company was founded in 2016 following a discovery made by Illumina in 2015 and has conducted large-scale clinical trials, including PATHFINDER 2 and the NHS-Galleri Trial, to validate the clinical utility of its testing technology.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage grail.com
Sector Healthcare IR page investors.grail.com
Tags
multi-cancer early detection, cell-free dna, methylation analysis, blood-based screening, oncology diagnostics, precision medicine, clinical trials, companion diagnostics, Galleri, Circulating Cell-free Genome Atlas, CCGA, PATHFINDER 2, NHS-Galleri Trial, Cirina
Press page grail.com/press-releases

Metrics

Valuation  
Market cap $ 6.088B
Market cap (USD) $ 6.088B
P/E -14.43
PEG —
P/BV 2.48
P/S 36.54
P/OCF -19.88
P/FCF -19.51
Dividend yield —
Turnover / mcap —
Returns  
ROE -16.1%
ROI -17.2%
ROIC -17.8%
Profit margin -277.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 57
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 147.172M 125.595M 93.105M 55.55M
Net profit -408.351M -2.027B -1.466B -5.399B
Free cash flow -299.916M -582.364M -608.687M -584.172M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 85.59 17.85 — —
Price performance 12m 3.79 — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 16.9M 20.3M 18.3M
↳ YoY growth +19.9% -9.9%
Lease liabilities (USD) — — 84.4M 68.1M 54.9M
Cash and deposits (USD) 226M 246M 97.3M 214M 250M
Intangible assets (USD) — — 2.69B 2.02B 1.85B
Right-of-use assets (USD) — — 84.4M 66.4M 52.1M
Cash flow detail
Operating cash flow (USD) — -561M -596M -577M -299M
Purchases of property, plant and equipment (USD) — -22.9M -12.9M -5.21M -909,000
Change in receivables (cash effect) (USD) — -8.68M -1.38M -3.37M 1.69M
Change in payables (cash effect) (USD) — 2.34M 2.89M -14.6M -2.73M
Income taxes paid (cash effect) (USD) — — — — -1.13M
Share-based compensation (USD) — 75.7M 97.2M 86.1M 58.3M
Operating cash flow before change in receivables (USD) — -553M -594M -574M -301M
Free cash flow (OCF - PPE - intangibles) (USD) — -584M -609M -582M -300M
Income detail
Research and development expense (USD) — 330M 339M 322M 196M
Total comprehensive income (USD) — -5.4B -1.47B -2.03B -407M
Comprehensive income to owners (USD) — -5.4B -1.47B -2.03B -407M
Reported Mar 5, 2025 Mar 5, 2025 Mar 5, 2025 Mar 5, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

GRAIL Reports Third Quarter 2026 Financial Results Bull 6 Bear 0 Results

Skip to content

November 4, 2026

FDA Advisory Committee Voted in Favor of Approval of GRAIL’s Galleri Multi-Cancer Early Detection Test

Q3 Galleri®Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000

Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million

SUNNYVALE, Calif. — Nov. 4, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.

Galleri test revenue for the third quarter grew 14% year-over-year to $37.3 million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test volume for the third quarter grew approximately 24% year-over-year to more than 56,000 tests. Total Galleri test volume and revenue for the nine months ended September 30, 2026 grew 36% year-over-year to more than 174,000 tests and 24% to $119.7 million, respectively. Net loss for the third quarter was $103.6 million. Gross loss was $18.1 million. Non-GAAP adjusted gross profit was $15.9 million, and non-GAAP adjusted EBITDA was $(92.6) million.1

“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee,” said Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL. “This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”

For the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, GRAIL reported:

  • Revenue: Total revenue, comprised of screening and development services revenue, was $37.5 million, an increase of $1.3 million or 4%.

  • Net loss: Net loss was $103.6 million, an increase of $14.6 million or 16%.

  • Gross loss: Gross loss was $18.1 million, an increase of $4.4 million or 32%.

  • Adjusted gross profit1: Adjusted gross profit was $15.9 million, a decrease of $4.1 million or 20%.

  • Adjusted EBITDA1: Adjusted EBITDA was $(92.6) million, an increase in adjusted EBITDA loss of $20.9 million or 29%.

  • **Cash position:**Cash, cash equivalents, and short-term marketable securities totaled $788.7 million as of September 30, 2026.

Recent business highlights include:

  • Announced a favorable vote for approval of the Galleri test from the FDA’s Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee (the “Advisory Committee”) in September. The company anticipates an FDA decision by early Q1 2027.

  • Published results from the NHS-Galleri trial in The New England Journal of Medicine and Nature Medicine, and final results from the PATHFINDER 2 study in Nature Medicine. The publications report clinical utility, test performance, and safety results from approximately 175,000 participants enrolled in the UK and North America. The results across the studies demonstrated:

  • Substantially increased cancer detection (4-6.5x more cancers detected) with robust performance, a favorable safety profile and consistent clinical performance across the two large trials.

  • Additionally, the NHS-Galleri trial demonstrated a substantial reduction of >20% in Stage IV diagnoses of 12 prespecified aggressive cancers and a 25% reduction in cancers diagnosed after emergency presentation in the Galleri arm compared to the control arm.

  • In the NHS-Galleri trial, Galleri added to standard-of-care screening detected more Stage I-II cancers than the UK national screening program found all cancers across all stages.

These data support the potential of multi-cancer early detection screening at population scale to identify cancers before symptoms appear — when they can be treated more easily and are potentially curable.

Conference Call and WebcastA webcast and conference call will be held today, Nov. 4, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may access it on the investor relations section of GRAIL’s website at investors.grail.com.

A replay of the webcast will be available on GRAIL’s website for 30 days.

About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL’s common stock is listed under the ticker symbol “GRAL” on the Nasdaq Stock Exchange.

October 27, 2026

PDF Version

SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m. ET.

GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured.

A live and replay webcast may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom.

By Meredith Hemler / October 20, 2026

October 20, 2026

SUNNYVALE, Calif., Oct. 21, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.

**Third Quarter 2026 Webcast and Conference Call Details
**A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL’s website at investors.grail.com .   

Please register for the live event here .

To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties. 

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. 

Prompts

GRAIL, Inc. (ticker GRAL), listed in United States.

ETFs Holding GRAIL, Inc.

ETF Weight in ETF Shares Market value As of
CBSE 2.59% 19,576 $ 1.342M Jul 31, 2026
HELX 1.09% 4,456 $ 304.211K Jun 30, 2026
ORR short -0.28% -9,677 $ -1.02M Nov 18, 2026
TMED 0.26% 868 $ 59.258K Jun 30, 2026
AVSC 0.25% 76,287 $ 8.056M Nov 16, 2026
FSEV 0.20% 195 $ 13.313K Jun 30, 2026
ESSC 0.18% 952 $ 65.269K Jul 31, 2026
PSC 0.12% 41,189 $ 2.812M Jun 30, 2026
FESM 0.11% 92,686 $ 6.328M Jun 30, 2026
DFAS 0.10% 280,301 $ 34.015M Nov 12, 2026
RESM 0.09% 46 $ 3,140.42 Jun 30, 2026
DXUV 0.04% 22,991 $ 2.79M Nov 12, 2026
AVUS 0.02% 20,768 $ 2.193M Nov 16, 2026
AVMC 0.02% 802 $ 84.691K Nov 16, 2026
MSSM 0.02% 1,779 $ 141.199K Aug 31, 2026
DFAC 0.02% 138,676 $ 16.828M Nov 12, 2026
PINK 0.02% 478 $ 50.611K Nov 17, 2026
IETC 0.01% 357 $ 37.699K Nov 16, 2026
DFAU 0.01% 9,985 $ 1.212M Nov 12, 2026
DCOR 0.01% 32,782 $ 3.978M Nov 12, 2026
DFUS 0.01% 13,404 $ 1.627M Nov 12, 2026
ACVF 0.00% 82 $ 5,621.92 Jul 31, 2026
DFUV 0.00% 3,458 $ 419.628K Nov 12, 2026
DFLV 0.00% 321 $ 38.953K Nov 12, 2026
AVSU 0.00% 27 $ 2,851.20 Nov 16, 2026